Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
110.47
+1.20 (1.10%)
At close: Sep 14, 2026, 4:00 PM EDT
110.47
0.00 (0.00%)
After-hours: Sep 14, 2026, 7:30 PM EDT
Inhibrx Biosciences Market Cap
Inhibrx Biosciences has a market cap or net worth of $1.63 billion as of September 14, 2026. Its market cap has increased by 307.85% in one year.
Market Cap
1.63B
Enterprise Value
1.67B
1-Year Change
307.85%
Ranking
Category
Stock Price
$110.47
ChartMarket Cap Chart
Since May 29, 2024, Inhibrx Biosciences's market cap has increased from $198.24M to $1.63B, an increase of 720.16%. That is a compound annual growth rate of 150.07%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 14, 2026 | 1.63B | 41.51% |
| Dec 31, 2025 | 1.15B | 415.39% |
| Dec 31, 2024 | 222.93M | 12.46% |
| May 29, 2024 | 198.24M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Recursion Pharmaceuticals | 1.72B |
| Braveheart Bio | 1.71B |
| Maravai LifeSciences Holdings | 1.70B |
| Immunocore Holdings | 1.68B |
| Intellia Therapeutics | 1.65B |
| Fortrea Holdings | 1.64B |
| Taysha Gene Therapies | 1.64B |
| Syndax Pharmaceuticals | 1.62B |